Neomycin Sulfate is an antibiotic used to reduce the risk of infection during surgery of the bowel. Neomycin is also used to reduce the symptoms of hepatic coma.
Neomycin Sulfate is the sulfate salt form of neomycin, a broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.
| Item |
Specification: USP41 |
Results |
| Characteristics |
A white or yellowish-white powder. Odorless or almost. Hygroscopic |
Complies |
| Identification |
A;B;C The positive reaction. |
Complies |
| Solubility |
Very soluble in water, insoluble in acetone,chloroform,ether. |
Complies |
| Acidity or alkalinity (PH) |
5.0-7.5 |
6.6 |
| Loss on drying |
≤8.0% |
5.2% |
| Assay |
≥600 I.U. /mg (DRY) |
661 I.U./mg DRY
627 I.U./mg MOIST |
| Conclusion: The product meets the requirements of USP41. |
About us:
China Sinopharm International (Shanghai) Co., Ltd. is a comprehensive commercial service enterprise centering international pharmaceutical business. It is a wholly-owned subsidiary under China Sinopharm International Corporation and is affiliated to China National Pharmaceutical Group Corporation (referred to as "Sinopharm Group"), a Fortune Global 500. Founded in 1985, the company has an net asset of nearly 200 million yuan. It has complete commercial facilities and 23,000 square meters of properties including an office building and shopping malls in Shanghai's West Nanjing Road commercial area and multiple warehouses.
International business are carried out based on the platforms of Sinopharm Group and Sinopharm International Pharmaceutical and aims to spread China's high-quality pharmaceutical products and services to the world. Through close cooperation with major domestic pharmaceutical companies, high-quality pharmaceutical products and overall solutions are provided to overseas customers. We are a well-known pharmaceutical enterprise in China with partners extending to more than 80 countries and regions around the world.
We have long been focusing on the field of medicine and health. Our main business covers overseas registration and import and export of pharmaceutical products such as preparations, APIs, medical devices and diagnostic reagents; export of pharmaceutical engineering equipment, production lines and technical services; import and export of health products, food additives and plant extracts. In 2017, the company's total import and export volume exceeded 300 million yuan. At present, we have obtained more than 20 overseas registration certificates for preparations, APIs and medical devices and assisted many domestic pharmaceutical companies for access to the international market.
Over the years, the company has always adhered to idea to be "professional, efficient, cohesive, progressive" and undertakes the mission to "create value, serve for customers and cultivate employees".Our strategic goal is to place customers as our center and become a world-class pharmaceutical import and export enterprise.
Audited Supplier 
){kind=link}
){kind=link}